Pharming Group Reports Strong 2024 Revenue Growth and Strategic Expansion

Pharming Group ( (NL:PHARM) ) just unveiled an update.

Pharming Group reported a 21% increase in total revenues for 2024, reaching US$297.2 million, surpassing their guidance. This growth was driven by record revenues from RUCONEST® and significant sales of Joenja® in its first full year. The company also completed the acquisition of Abliva AB, adding a promising treatment for primary mitochondrial diseases to its pipeline, aligning with its strategy to become a leading global rare disease company. With ongoing clinical trials and regulatory reviews, Pharming is poised for further growth in 2025, focusing on expanding its portfolio and reaching more patients.

More about Pharming Group

Pharming Group is a biotechnology company focused on developing and commercializing innovative products for the treatment of rare diseases. The company’s primary products include RUCONEST®, used for treating acute hereditary angioedema (HAE) attacks, and Joenja® (leniolisib), which targets primary immunodeficiencies. Pharming is committed to expanding its market presence and product offerings, particularly in the rare disease sector.

YTD Price Performance: -19.39%

Average Trading Volume: 1,679

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $526M

For an in-depth examination of PHARM stock, go to TipRanks’ Stock Analysis page.